China’s NMPA Accredited Beginning of Registration Testing of AnPac Bio Course III Professional medical System (For Lung Cancer Auxiliary Prognosis Utility)

SAN JOSE, Calif., Feb. 08, 2021 (Globe NEWSWIRE) — AnPac Bio-Health-related Science Co., Ltd. (“AnPac

SAN JOSE, Calif., Feb. 08, 2021 (Globe NEWSWIRE) — AnPac Bio-Health-related Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with functions in China and the United States centered on early most cancers screening and detection, declared today that on January 25, 2021, the Nationwide Professional medical Merchandise Administration (the “NMPA”), China’s professional medical product or service regulatory authority, has accredited for AnPac Bio to start the registration testing of its Course III lung cancer auxiliary prognosis health-related machine at a designated health-related system screening laboratory, which is a important step to getting a Course III healthcare device registration certificate by AnPac Bio. AnPac Bio began its health-related gadget registration software procedure in December 2018, by submitting an software for medical gadget classification with the NMPA. Considering the fact that then, AnPac Bio has obtained the perseverance of the product or service classification (advised as Class III) from the NMPA, and carried out clinical device optimization, interior health-related unit screening and external third occasion testing and validation, and attained the certification of designated inspection functionality from the specified clinical device registration screening laboratory. Once the clinical gadget passes the item registration screening, the up coming important phase will be a scientific demo. AnPac Bio ideas to carry out the scientific demo in at the very least two capable clinical trial professional medical institutions, every of which is predicted to enroll at minimum 300 subjects (covering the control team and the confirmed lung cancer group).

The previously mentioned-talked about Course III clinical machine is primarily based on AnPac Bio’s novel most cancers differentiation examination (CDA) technological know-how and has been employed in most cancers risk assessment checks of around 200,000 samples which include common inhabitants screening, as very well as retrospective and future medical scientific tests with top medical establishments. If AnPac Bio is successful in acquiring the Course III registration certification from the NMPA for its CDA system, AnPac Bio will also be able to penetrate the Chinese hospital market place as properly as other healthcare establishments for lung cancer auxiliary diagnosis exams, which will anticipate to additional fuel the Company’s growth in earnings.

Dr. Chris Yu, CEO and Chairman of AnPac Bio commented: “We are incredibly happy about this significant progress in our registration software for our Class III lung cancer auxiliary analysis health-related unit. This application is one of the most critical projects of AnPac Bio’s, alongside with our strategy to current market our CDA take a look at as a laboratory produced take a look at (LDT) by our US labs. A ton of assets and challenging function have been devoted to this challenge. We will go on to diligently transfer ahead the challenge.”

About AnPac Bio

AnPac Bio is a biotechnology enterprise concentrated on early most cancers screening and detection, with 128 issued patents as of June 30, 2020. With two qualified scientific laboratories in China and just one CLIA and CAP accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, which includes CDA (Most cancers Differentiation Examination), bio-chemical, immunological, and genomics exams. In accordance to Frost & Sullivan, AnPac Bio rated third around the globe and first in China among the firms presenting following-era early cancer screening and detection technologies in terms of the number of scientific samples for most cancers screening and detection, primarily based on close to 41,700 medical samples as of December 31, 2019. AnPac Bio’s CDA engineering platform has been revealed in retrospective validation studies to be ready to detect the threat of above 20 different cancer varieties with high sensitivity and specificity.

For a lot more data, please take a look at:

For investor and media inquiries, be sure to make contact with:

Phil Situation, Marketing and Trader Relations
Phone: +1-267-810-6776 (US)
Email: [email protected]

Investor Relations:
Ascent Investor Relations LLC
Tina Xiao, President
Mobile phone: +1-917-609-0333 (US)
Electronic mail: [email protected]

Secure Harbor Statement

This announcement incorporates forward-wanting statements inside of the which means of Portion 27A of the Securities Act of 1933 and Segment 21E of the Securities Trade Act of 1934. These forward-hunting statements are made underneath the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Firm’s foreseeable future economic and working efficiency. The Company has tried to recognize forward-on the lookout statements by terminologies such as “believes,” “estimates,” “anticipates,” “expects,” “designs,” “assignments,” “intends,” “probable,” “target,” “aim,” “predict,” “outlook,” “seek,” “goal” “objective,” “assume,” “contemplate,” “continue,” “positioned,” “forecast,” “likely,” “might,” “could,” “may well,” “will,” “should really,” “about” or other phrases that express uncertainty of long run situations or results to discover these ahead-searching statements. These statements are based on existing anticipations, assumptions and uncertainties involving judgments about, among other points, upcoming economic, competitive and industry conditions and future company choices, all of which are challenging or impossible to forecast precisely and quite a few of which are past the Company’s management. These statements also entail identified and unknown challenges, uncertainties and other aspects that may perhaps bring about the Company’s true final results to be materially various from those people expressed or implied by any ahead-searching statement. Regarded and unidentified hazards, uncertainties and other variables consist of, but are not restricted to, the implementation of our company model and progress methods trends and levels of competition in the cancer screening and detection sector our expectations pertaining to desire for and market place acceptance of our most cancers screening and detection exams and our skill to develop our purchaser foundation our capability to get hold of and preserve mental home protections for our CDA technology and our continued investigation and growth to preserve rate with technological innovation developments our ability to obtain and sustain regulatory approvals from the NMPA, the Food and drug administration and the appropriate U.S. states and have our laboratories licensed or accredited by authorities which include the CLIA our future organization development, financial situation and effects of functions and our capacity to attain financing cost-correctly probable changes of govt regulations common economic and organization problems in China and elsewhere our means to hire and sustain crucial staff our partnership with our main organization partners and consumers and the length of the coronavirus outbreaks and their prospective adverse effect on the financial situations and money marketplaces and our enterprise and financial efficiency, these as ensuing from decreased professional things to do because of to quarantines and journey limitations instituted by China, the U.S. and quite a few other international locations all over the planet to have the unfold of the virus. Furthermore, all ahead-seeking statements are subject to the “Risk Factors” in depth from time to time in the Firm’s most modern Annual Report on Sort 20-F and other filings with the U.S. Securities and Trade Fee. Since of these and other hazards, uncertainties and assumptions, undue reliance ought to not be put on these ahead-hunting statements. In addition, these statements speak only as of the date of this press release and, besides as might be needed by legislation, the Firm undertakes no obligation to revise or update publicly any forward-hunting statements for any reason.